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Abstract
Despite the considerable number of studies reported to date, the causative agents of pneumonia are not completely
identified. We comprehensively applied modern and traditional laboratory diagnostic techniques to identify microbiota in
patients who were admitted to or developed pneumonia in intensive care units (ICUs). During a three-year period, we tested
the bronchoalveolar lavage (BAL) of patients with ventilator-associated pneumonia, community-acquired pneumonia, non-
ventilator ICU pneumonia and aspiration pneumonia, and compared the results with those from patients without pneumonia
(controls).Samplesweretestedbyamplificationof16SrDNA,18SrDNAgenesfollowedbycloningandsequencingandbyPCR
to target specific pathogens. We also included culture, amoeba co-culture, detection of antibodies to selected agents and
urinary antigen tests. Based on molecular testing, we identified a wide repertoire of 160 bacterial species of which 73 have not
been previously reported in pneumonia. Moreover, we found 37 putative new bacterial phylotypes with a 16S rDNA gene
divergence $98% from known phylotypes. We also identified 24 fungal species of which 6 have not been previously reported
in pneumonia and 7 viruses. Patients can present up to 16 different microorganisms in a single BAL (mean 6 SD; 3.7762.93).
Some pathogens considered to be typical for ICU pneumonia such as Pseudomonas aeruginosa and Streptococcus species can
be detected as commonly in controls as in pneumonia patients which strikingly highlights the existence of a core pulmonary
microbiota. Differences in the microbiota of different forms of pneumonia were documented.
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Introduction
The cause of pneumonia in intensive care units (ICUs) remains
unknown in nearly 30% of cases despite extensive microbiological
investigations [1,2]. Microbial communities previously identified, in
deep respiratory samples, include bacteria, fungi and viruses for
which the role in the observed pathology is not clear. Microorgan-
isms frequently identified in respiratory samples from ICU-
pneumonia patients included Pseudomonas aeruginosa, Staphylococci,
Enterobacteria, Candida albicans, Influenza virus, Herpes simplex
virus (HSV) and Cytomegalovirus (CMV) [3–7]. In some
investigations, a pathogenic bacterium is isolated, whereas in other
cases, the number of colony forming units (CFU) is considered to
determine the pathogenic character [8]. Recently, the bacterial
microbiota of patients with cystic fibrosis and ventilator-associated
pneumonia (VAP) were studied using 16S rDNA gene amplification
followed by clone libraries sequencing [9–11]. Our laboratory has
contributed to this work and has shown, by different sequencing
approaches, that the microbial population of patients with cystic
fibrosis was more diverse than expected [10,11]. Here, we use a
comparable approach in order to study 185 episodes of ICU
pneumonia and 25 control cases. These patients were studied using
broad-range primer amplification of the 16S rDNA gene of bacteria
and the intergenic spacer of 18S rDNA gene of fungi followed by
cloning and sequencing. We also used specific quantitative PCR
(qPCR) to target fastidious bacteria and a spectrum of viruses.
Moreover, we tested samples from our patients by standardized
routine culture, amoebal co-culture, blood culture, ELISA targeted
antibody detection, immunofluorescent assay antigenemia and
antigenuria testing as routinely performed in such cases to compare
these routine tests with molecular approaches.
In preliminary results, we have reported the likely frequency of
Tropheryma whipplei and the occurrence of vegetable DNA in
pneumonia patients [12,13]. In this work, we highlight the
different compositions of microbiota in patients with four different
types of ICU-pneumonia.
Results
Bacterial microbiota as evaluated by 16S rDNA
Molecular assays were positive for at least one bacterium for 129
out of 185 bronchoalveolar lavage(BAL) samples from patients with
pneumonia as well as from 13 out of 25 from control individuals
(p=0.07). Bacterial clone libraries from amplified 16S rDNA genes
(nearly 4,000 clones that contained exploitable sequences were
included) identified 157 different bacteria at the species level.
Detailed data about the relative abundance and richness of each
species in their corresponding library are summarized in data S1
and S2 in supplementary informations. Bacterial clone libraries of
patients showed that 44 libraries were characterized by the presence
PLoS ONE | www.plosone.org 1 February 2012 | Volume 7 | Issue 2 | e32486of only one bacterium, 40 libraries were polybacterial but
dominated by one bacterium (50% of the clones in the library),
whereas 45 libraries were polybacterial without any dominant
bacterium (Fig. 1).Bacterial clone libraries of controls showed that 2
libraries were characterized by the presence of only one bacterium,
4 librarieswere polybacterialbutdominatedbyonebacterium(50%
of the clones in the library), whereas 7 libraries were polybacterial
but without any dominant bacterium (Fig. 1). Patients exhibited up
to15bacteriaintheirBALfluids(mean6SD;3.4862.80)(Tables1
and 2). Overall, patients exhibited 146 different species belonging to
7 different phyla (13 classes, 23 orders, 44 families and 71 genera) of
which 73 had not been previously observed in BAL from
pneumonia, whereas bacterial clone libraries of controls identified
38 species belonging to 4 different phyla (9 classes, 13 orders, 22
families and 27 genera). In patients, aerobic gram-negative bacilli,
gram-positive cocci, and anaerobic bacteria from oropharyngeal
flora were the most frequent bacteria identified (Tables
S1,S2,S3,S4, Fig. 2). Surprisingly, bacteria that are usually
associated with other diseases such as the gram-positive anaerobe
Atopobium vaginae, or from unexpected animal origins, such as
Enterococcus canintestini, were alsoc found. Moreover, 51 strictly
anaerobicbacteria(35%)werefoundinpatientsversus17anaerobic
bacteria (44%) found in controls (p=0.26). Among those bacteria
which were identified in controls, 24 bacteria were also identified in
patients (Fig. S1, Tables S2,S3,S4), including Pseudomonas aeruginosa
sequences respectively identified in 100% and 86% from 2 different
cloneslibrariesfrom2immunocompromisedcontrols.Inthesecond
clone library, the 14% of the remaining sequences included
Achromobacter xylosoxidans, which also is a typical bacterium of
nosocomial pneumonia. Stenotrophomonas maltophilia sequences were
found in 10% of clone library of another immunocompromised
control, along with 5 other bacteria. Similarly, sequences of
Streptococcus mitis (7% of the clone library) was identified along with
12 other bacteria in a control with acute respiratory distress
syndrome (ARDS) and a history of aspiration pneumonia (AP) 6
days before BAL sampling. Additionally, Arcobacter cryaerophilus,
Atopobium parvulum, Lachnospiraceae bacterium, Prevotella melaninogenica,
andPrevotella pallens weresignificantly more frequent incontrols than
in patients (p=0.01, 0.01, 0.001, 0.01 and 0.01 respectively) (Table
S4).
Bacterial clone libraries surprisingly showed 37 new phylotypes
with 16S rDNA sequence similarity lower than 98% to known
bacteria available in the GenBank database (Data S1 and S2).
Among them, 32 novel bacterial phylotypes were identified in
BAL from patients, whereas 5 novel phylotypes were identified in
BAL from controls (Fig. 3). Novel bacterial phylotypes identified in
patients were more diversified, as they belonged to 6 different
phyla including Bacteroidetes (11 phylotypes), Firmicutes (9 phylo-
types), Proteobacteria (9 phylotypes), Actinobacteria (one phylotypes),
Acidobacteria (one phylotype) and Spirochaetes (one phylotype). Novel
species identified in controls belong to Bacteroidetes (2 phylotypes),
Firmicutes (2 phylotypes) and Actinobacteria (one phylotype). Pre-
votellaceae phylotypes represent 24% of all novel phylotypes
identified and they were exhibited in patients with pneumonia as
Figure 1. Microbial profiles of positive BAL fluids from patients and controls.
doi:10.1371/journal.pone.0032486.g001
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BAL and blood culture are available Text S1.
Fungal microbiota as evaluated by the intergenic spacer
of 18S rDNA
At least one fungus was found in 31 BAL patient samples and in 6
from controls (p=0.37). Positive patients exhibit up to 5 fungi in
their BAL fluids (mean 6 SD; 1.4060.83) (Tables 1 and 2). Detailed
data about the relative abundance and richness of each species in
their corresponding library are also summarized in summary files
(Data S1 and S2) in supplementary informations. Fungal microbiota
obtained from patients showed the presence of 22 different species
belonging to 2 phyla (8 orders, 11 families and 12 genera) among
which 6 phylotypes had not been previously identified in BAL fluids
from pneumonia. Clone libraries from controls, identified 5 fungi
belonging to one phylum (2 orders, 4 families and 3 genera) among
Table 1. Summary of the number of bacteria, fungi and viruses identified by molecular assays in BAL fluids.
Pneumonia cohorts
Pneumonia patients
(n=185) CS (n=25)
CAP (n=32) VAP (n=106) NV ICU-P (n=22) AP (n=25)
Nu Bacteria/Sample
10–15 0 3 0 1 4 1
5–9 5 18 5 5 33 4
4 1 10 2 1 14 4
3 3 13 3 3 22 0
2 3 61 21 2 2
1 1 02 7 5 2 4 42
0 10 29 6 11 56 12
Nu species/positive sample 6 SD 2.6862.07 3.4962.87 3.4362.22 4.7863.68 3.4862.80 4.6162.95
Nu Fungi/Sample
5 1 00 01 0
3 0 01 01 0
2 1 23 17 1
1 2 16 2 3 23 5
0 2 8 8 81 6 2 21 5 4 1 9
Nu species/positive sample 6 SD 2.2561.89 1.1160.32 1.8360.75 1.2560.5 1.4060.83 1.1660.40
Nu Viruses/Sample
2 3 63 01 2 0
1 7 47 8 5 67 11
0 2 2 5 31 1 2 01 0 6 1 4
Nu species/positive sample 6 SD 1.360.48 1.1160.31 1.2760.46 160 1.1560.36 1.0960.30
CAP, community-associated pneumonia; VAP, ventilator-associated pneumonia; NV ICU-P, non-ventilator ICU pneumonia; AP, aspiration pneumonia; CS, control
subjects.
doi:10.1371/journal.pone.0032486.t001
Table 2. Microbiota composition of positive BAL fluids by molecular assays.
Pneumonia cohorts
Pneumonia
patients (n=185) CS (n=25) P value
CAP (n=32) VAP (n=106) NV ICU-P (n=22) AP (n=25)
Only bacteria 12 34 5 11 62 6 0.34
Only fungi 0 2 1 1 4 1 0.57
Only viruses 3 9 3 2 17 3 0.65
Bacteria and fungi 3 4 3 1 11 2 0.68
Bacteria and viruses 6 33 6 2 47 4 0.30
Fungi and viruses 0 4 0 1 5 3 0.02
Bacteria and fungi and viruses 1 7 2 0 10 1 0.76
Total positive samples 25 93 20 18 156 20 0.58
CAP, community-associated pneumonia; VAP, ventilator-associated pneumonia; NV ICU-P, non-ventilator ICU pneumonia; AP, aspiration pneumonia; CS, control
subjects.
doi:10.1371/journal.pone.0032486.t002
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the mostcommonfungalspeciesidentified(TablesS1,S2,S3 andS5).
Environmental fungi, which usually colonize water, food debris and
humid building surfaces, were more notably identified in our study
than in previous pneumonia studies. Furthermore, tree fungi
belonging to Basidiomycota phylum, Sporidiobolales sp., Cryptococcus
victoriae and Hyphoderma praetermissum, were found for the first time in
pneumoniaBALsamplesinthepresentstudy,whileCandidautilisand
Periconia macrospinosa were identified only in controls. Additionally,
Candida utilis was significantly more frequent in controls than in
patients (p=0.01). Results of fungi obtained using a routine BAL
culture are available in Text S1.
Viruses and fastidious bacterial pathogens detected by
qPCR
Four pneumonia patients were found to be positive for fastidious
bacteria Chlamydia pscitacii (1 case), Mycobacterium sp. (2 cases) and
Mycoplasma pneumoniae (2 cases) by qPCR. In addition, qPCR
Figure 2. The phylogenetic tree inferred from bacterial 16S rDNA sequences which were identified in all patients using the Neighbor-
Joining and the Kimura 2-parameter methods. Bacteria which were previously identified in pneumonia are shown in black. Bacteria which have
not been previously identified in pneumonia and which were identified in this study only in pneumonia patients are shown in red. Bacteria which have
notbeen previously identified in pneumonia patients andwhich were identified in this study in both pneumonia andcontrol patientsareshownin blue,
whereas bacteria which have been identified in this study only in control subjects and not in pneumonia patients are shown in green.
doi:10.1371/journal.pone.0032486.g002
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microorganisms identified by qPCR (loads or Cycle threshold) are
also provided and summarized in supplementary information
(Data S1 and S2). Our study showed that at least one virus was
identified in 74 BAL samples from patients, and 11 from controls
(p=0.95). HSV and CMV were the most commonly identified
viruses. While the prevalence of these two viruses in patients was
not significantly different from that of controls (Table S6), CMV
was more frequently identified in pneumonia patients than in
controls. HSV and CMV coinfection was found in BAL samples
from 5 VAP patients, 2 community-acquired pneumonia (CAP)
patients and 2 non-ventilator ICU pneumonia (NV ICU-P)
patients and one control subject. Coinfection with CMV and
respiratory syncytial virus type A was detected in a BAL from one
NV-ICU-P patient, and both HSV and VZV were identified in a
BAL from a CAP patient. Rhinovirus was identified in a control
with ARDS, urinary infection and sinusitis. Parainfluenza virus-1
was detected in 3 VAP patients and an immunocompetent control
with a pulmonary contusion. Results obtained using routine
serology and antigenemia for viruses and fastidious pathogens are
available in Text S1
Comparison of the microbiota between pneumonias and
controls
Overall, bacterial difference between patients and controls
showed that bacteria belonging to Bacilli and Gammaproteobacteria
were dominant in patients, whereas anaerobic bacteria related to
Bacteroidia (represented essentially by Prevotella species) and Clostridia
were dominant in controls (Fig. 4) (p,0.01). Mollicutes, which are
represented by the Mycoplasma genus, were only detected in
patients with CAP and VAP (Fig. 4). As for fungal species,
members of Saccharomycetes were ubiquitously identified in all
cohorts. Eurotiomycetes, which are represented by Aspergillus,
Penicillium and Cladophialophora genera, were dominant in the
CAP cohort (Fig. 5). Tremellomycetes, represented by the Cryptococcus
genus, was only identified in the NV-ICU-P cohort, whereas
Figure 3. A phylogenetic tree inferred from 16S rDNA sequences of novel bacterial phylotypes. These novel phylotypes exhibited
sequence similarities of less than 98% to known bacteria available in the GenBank database, and they were classified in silico using ‘‘Classifier’’
program. Phylotypes are reported according to their genus or by the last possible classification determined by the program. When possible,
phylotypes with the same classification are clustered together. The frequency of phylotypes in each cohort is shown on the right.. Bacteroidetes are
shown in purple, Firmicutes in red, Proteobacteria in blue, Actinobacteria in yellow, Acidobacteria in orange and Spirochaetes in green. CAP,
community-acquired pneumonia; VAP, ventilator-associated pneumonia; NV ICU-P, non-ventilator ICU pneumonia; AP, aspiration pneumonia; and CS,
control subjects.
doi:10.1371/journal.pone.0032486.g003
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ascomycetes) were only identified in the VAP cohort. In addition,
Sordariomycetes, which is represented by the Periconia genus, was only
identified in controls.
At the specie-level, 58 bacteria, 7 fungi and 5 viruses were
common to at least two cohorts, among which Pseudomonas
aeruginosa, Streptococcus mitis, Prevotella melaninogenica, Peptostreptococcus
stomatis, Candida albicans and HSV were commonly identified
irrespective of cohorts, whereas Haemophilus influenzae, Staphylococcus
aureus, Streptococcus genomosp. C4, Streptococcus parasanguinis and
Streptococcus pneumoniae were commonly identified in patients
regardless of pneumonia type (Fig. S2). Additionally, 24 bacteria,
3 fungi and 3 viruses were common to controls and at least one
pneumonia cohort, whereas 34 bacteria, 4 fungi and 2 viruses were
common to at least two pneumonia cohorts (Fig. S2). In contrast,
many microorganisms (102 bacteria, 17 fungi and 2 viruses) were
restricted to one of cohorts (17 bacteria and 5 fungi only were
identified in the CAP cohort; 54 bacteria and 6 fungi only were
identified in the VAP cohort; 8 bacteria, 4 fungi and one virus only
were identified in the NV ICU-P cohort; 9 bacteria only were
identified in the AP cohort; 14 bacteria, 2 fungi and one virus only
were identified in controls) (Fig. S2).
Abundance and specie richness in the libraries and
correlation with clinical data
Microbial profiles of positive pneumonia BAL fluids showed
that 40 (25%) were characterized by the presence of one
microorganism, whereas 116 (75%) were polymicrobial. In
controls, 4 (20%) of BAL fluids were characterized by the
presence of one microorganism, whereas 16 (80%) were
polymicrobial (Data S1 and S2). Available clinical data for
patients and controls showed that monobacterial patients were
more frequently, but statistically insignificant, subjected to initial
antibiotic therapy than polymicrobial ones (p=0.12; Table 3 and
Table S7). In ventilated subjects, monomicrobial patients have a
slightly shorter period of mechanical ventilation prior to the
pneumonia episode as compared to polymicrobials. Monomicro-
bial controls have a remarkably shorter period of mechanical
ventilation before sampling compared to polymicrobials (p=0.25;
Table 3). The same observation was showed for length of ICU stay
prior to sampling and for total length of hospital stay. According to
these observations, the polymicrobial profiles of controls seem to
be partially related to the high duration of ICU stay before
sampling. However, the ICU mortality was higher in mono-
microbial patients than in polymicrobial ones (p=0.02). The ICU
mortality rate was higher in pneumonia patients for whom BAL
fluids exhibited only viruses or fungi, or both than in mono-
bacterial or polybacterial patients (p=0.01; Table S7). A higher
but not statistically significant ICU mortality was also observed in
pneumonia patients for whom BAL fluids exhibited only viruses or
fungi, or both than in controls with the same profile (p=0.07;
Table S7).
Comparison of lung microbiota between different
studies
We next compared the bacterial communities found in our
study to those found in lung specimens in five previous studies
which were based on 16S rDNA amplification [9,11,14–16].
Comparative analyses of lung microbiota between these studies
showed that 147 different genera were found in all of them.
Among these genera, 70 genera are widely distributed within the
studies including Gemella, Haemophilus, Megasphaera, Neisseria,
Porphyromonas, Prevotella, Pseudomonas, Staphylococcus and Streptococcus
genera which have commonly been found irrespective of study. In
contrast, 77 genera were restrictively identified across the studies
(Table 4). However, at the species level (only the studies that
determined bacterial species were included [9,11,14]), compara-
tive analyses showed that from 59 bacteria commonly distributed
within the studies, Escherichia coli, Haemophilus influenzae, Prevotella
oris, Pseudomonas aeruginosa, Staphylococcus aureus and Streptococcus mitis
were commonly found in the four studies. In contrast, 291 bacteria
were restrictively identified across the studies (Fig. S3). Conse-
quently, comparative analysis at the specie-level showed that some
bacteria, such as Pseudomonas aeruginosa and Staphylococci, are
commonly found in pulmonary specimens. However, the pattern
of distribution of many other species is distinctly heterogeneous
and depending on the specific study and disease. Variation of lung
microbiota, from one individual to another and from one study to
another, suggests that the repertoire of microorganisms associated
with respiratory infections still remains incompletely understood.
Discussion
Previous studies performed on respiratory specimens showed
that unexpected bacteria are increasingly identified, as well as
studies describing isolated cases of respiratory infection due to an
unexpected bacterium that was detected using molecular tech-
niques [9,11,14,17–20]. This study extends the analyses to
bacteria, fungi and viruses in a large population of ICU
pneumonia using comprehensive molecular testing. Our results
demonstrate that nearly 50% of the microbial species found had
not been previously reported in lung samples from pneumonia.
Therefore, the composition of ICU-pneumonia microbiota is more
complex, more extensive and more diverse than originally
expected.
However, we raise the question on the actual role of these
microorganisms in pneumonia. Indeed, our study reveals that
some pathogens that till now had been considered typical for ICU
pneumonia, such as Pseudomonas aeruginosa and Streptococcus species,
or viruses, such CMV and HSV, can be detected as commonly in
controls as in patients (Fig. S1 and S2). This result is emphasized
by more recent studies by Erb-Downward et al. and Hilty et al.
who showed that a community of lung-resident bacteria including
Pseudomonas and Streptococcus genera can be identified in patients
with chronic obstructive disease or asthma, as well as in healthy
people [15,16]. Our study agrees with the recent literature and
highlights the existence of a core pulmonary microbiota,
confirming the non-sterility of the lung [15,16].
More interestingly, we showed that pulmonary microbiota
heterogeneity can be observed between patients and controls,
among pneumonia cohorts and among patients within the same
cohort. High pulmonary microbiota heterogeneity was also
observed between our study and other previous works performed
on cystic fibrosis or VAP [9,11,14] (Fig. S3). We found that some
bacteria were commonly identified in all studies, whereas many
others were only identified in one study, and most of these were
Figure 4. Differences in bacterial microbiota composition between community- acquired pneumonia (CAP), ventilator-associated
pneumonia (VAP), non-ventilator ICU pneumonia (NV ICU-P), aspiration pneumonia (AP) and control subjects (CS) cohorts. Bacteria
are shown according to their classes. Distribution of bacterial classes in each cohort is expressed as a percentage. Bacterial classes and their
corresponding colours are indicated in the bottom right corner.
doi:10.1371/journal.pone.0032486.g004
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between individuals, depending on underlying diseases, habits
and geographic origin. Additionally, these unexpected microor-
ganisms may explain a lack of response to drug therapies in some
pneumonia patients. Therefore, the possible extension of empiric
treatments to cover a large spectrum of microorganisms, especially
for patients who do not respond adequately to initial treatment, is
questionable.
Another interesting observation was that mixed infection was
observed in many BAL fluids from pneumonia patients.
Interestingly, recent works report that probable interactions
between parasitic species can occur in their host, and these
reports also show that infection with a given microorganism may
increase or decrease susceptibility to infection by another one or
can create a cross-immunity response [21–27]. Such interaction
remains to be investigated.
Moreover, by comparing molecular testing to standard routine
methods, this study reveals that many pneumonia-associated
pathogens are fastidious or uncultured and highlights a wide
discrepancy between culture and molecular microorganism
repertoire. Our study also shows that the molecular assay remains
a more efficient method to detect microorganisms in the
pneumonia samples, independently of atmospheric conditions
and medium nutrient supplements, which are particularly
important for culture, especially for fastidious microorganisms.
In addition, microorganism diagnosis was obtained for 156 (84%)
episodes of pneumonia by molecular tools compared with 120
(65%) pneumonia episodes for which microorganism diagnosis was
successfully done by culture (Table S8). In particular, molecular
tools seem to be far more sensitive than culture for bacterial
detection. This observation is based on the high number of
microorganisms, especially bacteria which were identified by
molecular methods compared with those detected by culture. In
fact, standard and special BAL cultures identified few, essentially
easily-grown and strictly aerobic or facultative anaerobic bacteria
(23 species) compared to molecular tools which identified 160
bacterial species (p,0.001) (Fig S4 and S5). Molecular tools
enabled the identification of unexpected bacteria which usually
colonize vaginal tracts, such as Atopobium vaginae and Peptoniphilus
lacrimalis, or of other bacteria coming from unexpected animal
origins, such as Chlamydia pscittasi, Enterococcus canintestini and
Streptococcus bovis, or of potentially known to be associated with
other diseases, such as Tropheryma whipplei, which were not
identified by culture. Furthermore molecular tools allowed the
detection of pathogenic bacteria such as Mycobacterium sp. and
Mycoplasma pneumoneae, for which identification attempts by culture
using specific media were failed due to culture biases. Moreover,
all bacteria that were first associated with pneumonia in the
present study were exclusively identified by molecular methods.
These findings are coherent to results from previous studies on
bacterial communities of respiratory diseases, including pneumo-
nia, which showed that molecular assays are more sensitive than
culture [9,11,14]. However, although molecular approaches
identified more fungal species than culture, fungal diagnoses were
Figure 5. Differences in fungal microbiota composition between community-associated pneumonia (CAP), ventilator-associated
pneumonia (VAP), non-ventilator ICU pneumonia (NV ICU-P), aspiration pneumonia (AP) and control subjects (CS) cohorts. Fungi
are presented according to their classes. Distribution of fungal classes in each cohort is expressed as a percentage. Fungal classes and their
corresponding colours are indicated in the bottom right corner.
doi:10.1371/journal.pone.0032486.g005
Table 3. Clinical data in monomicrobial and polymicrobial episodes.
Pneumonia patients (n=135/185) Control subjects (n=22/25)
Monomicrobial Polymicrobial Monomicrobial Polymicrobial
Case number 32 82 3 15
Age, yr (SD) 58.5 (13.9) 62.9 (14.7) 74 (13.4) 54.2 (17.3)
Male gender 16 46 3 7
Female gender 16 36 0 8
Immunocompromized 15 20 1 4
ARDS 15 19 0 4
CPIS (SD) 3.7 (1.8) 3.6 (1.7) 4.6 (0.5) 4 (1.4)
SOFA score (SD) 6.9 (3.1) 6.7 (3.6) 6.3 (3.7) 5.4 (2.6)
Radiologic score (SD) 5.5 (2.9) 4.8 (3.2) 3.6 (3.2) 5.3 (2.8)
Temperature, uC (SD) 37.6 (1) 37.8 (1.7) 37.2 (1.2) 37.6 (1.4)
Initial antibiotic therapy 18 33 2 9
Less than 2 days prior to sampling 6 17 0 3
3 days or more prior to sampling 12 16 2 6
Length of ICU stay prior to sampling, d (SD) 6.1 (9.1) 6.3 (10) 1.6 (1.1) 13.1 (15.6)
Total length of hospital stay, d (SD) 26 (29.7) 28.2 (23.3) 4.3 (1.5) 36.6 (35.9)
Length of MV prior to sampling, d (SD) 6.8 (10.3) 7.1 (11.2) 1.3 (0.5) 6.3 (7.2)
Sepsis 7 19 0 3
Septic shock 15 38 1 7
ICU mortality (%) 16 (50) 23 (28) 1 (33) 3 (20)
doi:10.1371/journal.pone.0032486.t003
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with 31 (17%) pneumonia episodes for which fungal diagnosis was
successfully obtained using molecular tools. Thus, fungal BAL
culture was more sensitive to detect some cultured fungi, such as
Candida species, than molecular approaches.
Another important finding was the high number of novel
bacterial species never previously described to date (bacteria with
BLASTn similarity less than 98%). This result is concordant with
similar studies of pneumonia and cystic fibrosis subjects [9,14] and
shows that in respiratory infections, more complex bacteria
populations can exist, among which novel bacteria had never
been previously identified. Moreover, this finding was also
supported by other studies performed on endodontic infections,
demonstrating that many novel bacteria essentially resident in the
oropharyngeal and dental plaque flora can be detected in these
infections [28,29]. The oropharyngeal and dental plaque flora is
potentially suspected to be a reservoir and, thus, the source of ICU
pneumonia pathogens, which could suggest that these novel
bacteria were inhaled through oropharyngeal tracts [30,31].
Nevertheless, molecular tools alone cannot give positive results
in some cases, or they could just identify microorganisms known to
be commensal or less pathogenic, where it may be useful to
perform other tests, such as serology. This was the situation for 5
pneumonia patients for whom serology provided evidence for
influenza A virus infection, whereas qPCR performed on their
BAL fluids was negative. Moreover, by combining culture-based
methods, blood culture and serology to molecular approaches we
significantly increase the probability to detect microorganisms in
the pneumonia episodes. In fact, by using these exhaustive
laboratory diagnostic tools, we failed to identify a microbial agent
in only 7% of the pneumonia episodes, which is significant when
compared to previous studies where the microbial agent was not
found in more than 30% of episodes of pneumonia (p,0.001)
[32]. However, the clinical significance of these microorganisms
and their role in the etiology of pneumonia remain difficult to be
cleared as their correlation with the disease causation remains to
be studied and confirmed in the future. Nevertheless, our findings
suggest that it would be highly recommended to develop a rapid
molecular test to target, besides typical pathogens, potential
pathogens known to be fastidious or uncultured (such as anaerobic
ones), and that it would be useful to add it to existing routine
standard techniques.
In summary, our study reveals that the respiratory microbiota is
more complex than expected.
Materials and Methods
Patients and clinical samples
A large study was implemented in our laboratory over a three-
year period (January 2007 through December 2009) to perform an
exhaustive etiologic diagnosis of pneumonia. The study involved
three ICUsinthe publichospitals ofMarseille,France(Onemedical
ICU and two medico-surgical ICUs). A total of 185 BAL fluids, 185
blood samples and 185 urinary samples from 130 ICU pneumonia
patients were studied. A diagnosis of community-acquired pneu-
monia, ventilator-associated pneumonia and aspiration pneumonia
was defined as previously described [32–34]. BAL and blood
sampling were performed as previously described [35]. A cohort of
25 ICU patients without pneumonia was studied as controls.
Pneumonia patients exhibited 32 episodes of community-associated
Table 4. Comparison of lung microbiota between different studies.
Lung microbiome studies (only lung samples)
Our study Harris et al. [9] Bittar et al. [11]
Bahrani-
mougeot
et al. [14]
Erb-Downward
et al. [15]
Hilty
et al. [16]
Studied diseases ICU pneumonia CF CF VAP COPD Asthma
Nu of studied individuals 210 (140 positive
cases)
57 (42 positive cases) 29 39 (16 positive
cases)
20 (14 BAL; 6
explants)
24
Nu of cases 185 (129 positive
cases)
36 (28 positive cases) 25 39 (16 positive
cases)
10 (4 BAL; 6
explants)
11
Nu of controls 25 (13 positive cases) 21 (14 positive cases) 4 No 10 (BAL) 13
Profile of controls Without pulmonary
infections
With pulmonary
infections
With bronchiectasis No Smokers and non
smokers healthy
peoples
COPD and
healthy
controls
Type of samples BAL BAL Sputa BAL BAL and lung
explants
Left upper
lobe brush
Nu of determined species 160 121 57 53 ND 20
Total Nu of genera 81* 56 34 28 74 39
Nu of genera common to other studies 60 42 29 24 43 37
Nu of genera restrictive to each study 21 14 5 4 31 2
Nu genera/patients 76 37 12 28 51 31
Nu genera/controls 28 41 31 No 46 30
Nu genera common to Pts and Cs 21 22 9 No 21 20
Mean genera/patient 6 SD 2.8862.20 ND 562.41 ND ND ND
Mean genera/control 6 SD 3.8462.26 ND 5.7560.95 ND ND ND
CF; Cystic fibrosis, COPD; Chronic obstructive pulmonary disease, ND; not determined,
*; included novel phylotypes successfully classified at the genus level.
doi:10.1371/journal.pone.0032486.t004
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episodes of non-ventilator ICU pneumonia and 25 episodes of
aspiration pneumonia. Further clinical data are summarized in SI
Table S9. Written informed consent was obtained from patients’
family members. The project was approved by the Local Ethics
Committee (comite ´ d’e ´thique de l’institut fe ´de ´ratif de recherche ´d e
laFaculte ´d eM e ´decinede Marseille(IFR48, Marseille, France), and
the permit number was 07–026.
Table 5. Primers and probes used in molecular assays.
Microorganisms Gene Forward primer Reverse primer Probe
Bacteria
Universal bacteria 16 s
rRNA
59-CAGCAGCCGCGGTAATAC-39 59-ACGGCTACCTTG TTACGACTT-39 Cloning and sequencing
Legionella sp. mip 59-GGGRATTVTTTATGAAGAA-
GARAYTGG-39
59-TCRTTNGGDCCDATNGGNCCDCC-39 Sequencing
Mycobacterium sp. ITS 59-GGGTGGGGTGTGGTGTTTGA-39 59-CAAGGCATCCACCATGCGC-39 59-TGGATAGTGGTTGCGAGCATC-39
M. tuberculosis 59-GCTAGCCGGCAGCGTATCCAT-39
M. avium group 59-GGCCGGCGTTCATCGAAAT-39
Afipia sp. rpoB 59-TGAAGATGGTCAAGGTCTTCG T-39 59-GTC CGACTTSA HGTCAGCAT-39 Sequencing
Bosea sp.
Bradyrhizobium sp.
Parachlamydia sp. ADP 59-TAG TGATCTGCTACGGGATTT-39 59-TTG GATTAGGATATTGCAATT T-39 59-AACCTTGTAGAAGTAACCTGGAAG-
AACCAGC-39
Azorhizobium sp. nodA 59-TGCATAATTACTGTGCACCAGAG-39 59-TCAACACCCTCTGGCCAACG-39 Sequencing
Mesorhizobium sp. 16 s rRNA 59-GGAGCTAATACCGTATACGTC-39 59-CAAGTAAACTTGCCAACGGCTAG-39 Sequencing
B. alpica Cpn60 59-CGCTGCAGCGGTAGTTGAGC-39 59-TAAGGACTATCCAGCTCAGC-
AGACATAT-39
Sequencing
C. burnetii IS1111 59-CAAGAAACGTATCGCTGTGGC-39 59-CACAGAGCCACCGTATGAATC-39 59- CCGAGTTCGAAACAATGAGGGCTG-39
C. pneumoniae omp2 59-GATTCGTCGCTAGTGCGGA-39 59-GTCTAACCTTCTTCGCTGTCA-39 59-ACAAAGCCAGCACCTGTTCCT-39
C. psittaci omp2 59-TTCTGTGATAAAGAATTTTATCCT-39 59-CGGACACAATACATTTTGCCG-39 59-CCAGTGCCAACCAGTAGACGCTA-39
M. pneumoniae Enolase 59-ATGTCCCGCTCCGAACGAA-39 59-CCAATTCCAGTTCAATTTGCAA-39 59-TGCCAAATACAATCGC-39
Fungi
Universel fungi ITS 59-TCCGTAGGTGAACCTGCGG-39 59-GCTGCGTTCTTCATCGATGC-39 Cloning and sequencing
Aspergillus sp. 28S rDNA 59-CTCGGAATGTATCACCTCTCGG-39 59-TCCTCGGTCCAGGCAGG-39 59-GTCTTATAGCCGAGGGTGCAATGCG-39-
Pneumocystis
carinii
DHFR 59-GTTGCACTTACAACTTCTTATGG-39 59-TAGATCCAGAGATTCATTTCGAG-39 Sequencing
Viruses
Mimivirus Capside 59-GATAAACATTATGGTGACTG-39 59-AGGAACATACAGAGTATATG-39 59-ATCATGAAAAGGGTCTTGCTA-39
RSV A Gene n 59-AGATCAACTTCTGTCATCCAGCAA-39 59-GCACATCATATTTAGGAGTATCAAT-39 59-CTTTGCCATACTCAATGAACAAAC-39
RSV B Gene n 59-AAG TGCAAATGATAAATTC-
ACAGGA-39
59-TAGTATCCAGCATCTTTAAGTZTCT-
TTATAG-39
59-CACCATCCAACGGAGCAGAGGAGAT-39
Influenza A Gene m 59-GGACTGCAGCGTAGACGCTT-39 59-CATYCTGTTGTATATGAGGCCCAT-39 59-CTCAGTTATTCTGCTGGTGCACTTGCCA-39
Influenza B Gene h 59-AATACGGTGGATTAAATAGCAA-39 59-CCAGCAATAGCTCCGAAGAAA-39 59-CACCCATATTGGGCAATTTCCTATGGC-39
Parainfluenza 1 Hg/Ne 59-CATTATCAATTGGTGATGC-39 59-CTTAAATTCAGATATGTATCCTG-39 59-CTTAATCACTCAAGGATGTGCAGATATA-39
Parainfluenza 3 Hg/Ne 59-CTCGAGGTTGTCAGGATATAG-39 59-CTTGGGAGTTGAACACAGTT-39 59-AATAACTGTAAACTCAGACTTGGTAC-
CTGACTT-39
Rhinovirus 59 NCR 59-GCACTTCTGTTTCCCC-39 59-GGCAGCCACGCAGGCT-39 59-AGCCTCATCTGCCAGGTCTA-39
Metapneumovirus Gene N 59-AACCGTGTACTAAGTGATG-
CACTC-39
59-CATTGTTTGACCGGCCCCATAA-39 59-CTTTGCCATACTCAATGAACAAAC-39
Enterovirus 59NC 59-CCCTGAATGCGGCTAATCC-39 59-ATTGTCACCATAAGCAGCCA-39 59-CADGGACACCCAAAGTAGTCGGTTCC-39
Coronavirus OC-43 Pol 59-CGCCGCCTTATTAAAGATGTTG-39 59-GGCATAGCACGATCACACTTAGG-39 59-AATCCTGTACTTATGGGTTGGGATT-39
Coronavirus 229-E Pol 59-TGGAGCGAGGATCGTGTTC-39 59-TAGGCTGTGACAGCTTTTGCA-39 59-TGTTCTCACGCTGCTGTTGATTCGCT-39
Coronavirus NL-63 Replicase 59-TGTTGTAGTAGGTGGTTGT-
GTAACATCT-39
59-AATTTTTGTGCACCAGTATCAAGTTT-39 59ATGTTTCACCAATTGTTAGTGAGAAAAT-
TTCTGTTATGGA-39
HSV Pol 59-CATCACCGACCCGGAGAGGGAC-39 59-GGGCCAGGCGCTTGTTGGTGTA-39 59-CCGCCGAACTGAGCAGACACCCGCGC-39
VZV Pol 59-GGTTAAACGTTTGAATCCATCC-39 59-CAGCAGACTTTCTCGAACGT-39 59-ATGCCACCTTTACAGTTGGAGGAA-39
CMV pp65 59-GCAGCCACGGGATCGTACT-39 59-GGCTTTTACCTCACACGAGCATT-39 59-CGCGAGACCGTGGAACTGCG-39
doi:10.1371/journal.pone.0032486.t005
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sequencing
Bacterial and fungal DNA extraction from BAL samples was
performed on a MagnaPure LC workstation (Roche Diagnostics,
Meylan, France), using a MagNa Pure LC DNA Isolation Kit II
(Roche Diagnostics) as previously described [12]. Viral nucleic
acids were extracted from 200 mL of BAL fluids using an MDX
workstation and the QIAamp Virus BioRobot MDx Kit according
to the manufacturer’s instructions. DNA was tested by PCR for
bacteria using broad-range primers targeting the 16S rDNA gene;
PCR was also used to test for universal fungi using broad-range
primers targeting intergenic spacer of 18S rDNA gene (Euro-
gentec, Seraing, Belgium) (Table 5). PCR product was cloned and
approximately 48 clones were screened per library. PCR, cloning
and sequencing were performed as previously described [12]. The
obtained sequences were assembled and analyzed by chromaspro
software and then BLASTed against those available in the
GenBank database (www.ncbi.nlm.nih.gov) for species identifica-
tion. Chimeric sequence search was performed with Black Box
Chimera Check (B2C2) program [36] and by examining the
BLAST profile of each sequence. Suspected chimeric sequences
were discarded from the study. Sequences showing a similarity of
.98% were considered to be known species, whereas sequences
showing a similarity of ,98% were considered to be novel species.
Legionella sp., Afipia sp.,Bradyrhizobium sp., Azorhizobium sp.,
Mesorhizobium sp., Balneatrix alpaca and Pneumocystis carinii were
tested by PCR using specific primers followed by sequencing of
PCR products (Table 5). The sequences have been deposited in
the GenBank database (accession Nu JF893554–JF893750).
BAL and blood cultures and phenotypic identifications
Standard bacteriological BAL culture and blood culture as
phenotypic identification of isolated bacteria were performed as
previously described [11,37]. A 10
4 CFU cut-off defined a positive
BAL culture. Blood culture were processed as previously described
[37]. Identification of fungi present in BAL or blood samples was
performed using a standard culture as previously described
[38,39]. Viral culture for Cytomegalovirus, herpes simplex virus,
parainfluenza viruses (types 1 and 3), respiratory syncytial virus,
varicella-zoster virus, influenza viruses (type A and B), and
enterovirus was performed using shell-vial culture as previously
described [4,40]. Amoeba co-culture were performed in micro-
plates on Acanthamoeba polyphaga as previously described [41].
Tentative isolations of Mycobacterium sp., Legionella sp. and
Mycoplasma pneumoniae were performed by using Bactec 9000 MB
automate, BCYE agar plates and SP4 medium as previously
described [42–44]. Results obtained using routine culture are
available in Table S10,S11,S12).
Quantitative PCR detection
Mycobacterium sp., M. tuberculosis, M. avium group, Bosea sp,
Parachlamydia sp., Coxiella burnetii, Chlamedia pneumoniae, Chlamedia
psittaci, Mycoplasma pneumoniae, Aspergillus sp., Mimivirus, CMV,
HSV, parainfluenza viruses 1 and 3, respiratory syncytial virus,
rhinovirus, metapneumovirus, varicella-zoster virus, influenza
viruses A and B, enterovirus, and coronaviruses OC-43, 229-E
and NL-63 were detected using quantitative PCR. Quantitative
PCR was performed using a LightCyclerH instrument (Roche
Diagnostics, Meylan, France) in conjunction with the QuantiTect
Probe PCR Kit. Primers and probes used to identify these
microorganisms are reported in table 5. The reaction was
performed as previously described [13]. For RNA viruses, RNA
was first reverse transcribed using MultiScribe
TM Reverse
Transcriptase (Applied Biosystems, Courtaboeuf, France) as
previously described [13].
Serology and urinary antigen assay
Sera from patients were tested by Immunofluorescent assay (IFA)
for Coxiella burnetii, Bartonella quintana, Bartonella henselae, Legionella
pneumophila, Legionella anisa [40,45,46]. Viral serologies for adenovi-
rus, cytomegalovirus, herpes simplex, parainfluenza viruses 1 and 3,
varicella-zoster virus and, influenzavirusesA and B wereperformed
using standard serologic methods (Immunofluorescent assay or
enzyme linked immunosorbent assay) [4]. Hemagglutination
inhibition, Immunoperoxidase staining and ELISA techniques were
used in-house to identify Aspergillosis. L. pneumophila antigenuria
and CMV pp65 antigenemia were tested for as previously reported
[4,47]. Results obtained using routine serology and antigenemia for
viruses and fastidious pathogens are available in Table S13.
Phylogenetic and statistical analysis
Bacterial and fungal nucleic acid sequences obtained from
broad-range primer PCR were aligned with BioEdit program
(http://www.mbio.ncsu.edu/BioEdit/bioedit.html) and phyloge-
netic trees were create with MEGA software version 4.1 using the
neighbor-joining method and the Kimura-2 parameter [48].
Species having sequence similarities ,98% with those available
in GenBank databases were also blasted and classified in silico using
‘‘Classifier’’ program in the Ribosomal Database Project (http://
rdp.cme.msu.edu/) [49]. Statistical analyses were performed using
Chi square test, Fisher’s exact test, students t-test or Mantel-
Haenszel’s Chi square test when appropriate. P values that were
less than or equal to 0.05 were considered significant.
Key words used for literature search
The PubMed database (www.ncbi.nlm.nih.gov/pubmed/) and
Google website (http://www.google.fr/) were used to search
whether species identified in ourstudy had beenpreviously reported
in cases of pneumonia for articles published between 1977 and
March 2010, with the combined search term ‘‘species name’’ and
‘‘pneumonia’’, ‘‘lung’’ or ‘‘infection.’’ Additional articles were
identified by hand-searching the references of selected papers.
Additional search terms included ‘‘microbiology’’, ‘‘diagnosis’’,
‘‘16S’’ and ‘‘molecular detection’’ were used. Only publications in
English were considered. Papers in languages other than English
were considered only when their abstracts in English were available.
Supporting Information
Figure S1 Schematic representation of microorganisms
commonly identified in pneumonia and control cohorts,
and those only detected in one cohort. Fungi are shown in
rectangles, viruses in octagons, and bacteria in circles. The name
of each microorganism is indicated.
(TIF)
Figure S2 Schematic representation of microorganisms
that were commonly identified between each pneumonia
form and controls, and those which were detected in
only one cohort. Fungi are shown in rectangles, viruses in
octagons, and bacteria in circles. Actinobacteria are shown in red,
Bacteroidetes in yellow, Chlamydiae in orange, Firmicutes in green,
Fusobacteria in purple, Proteobacteria in blue and Tenericutes in sky
blue. CAP, community-acquired pneumonia; VAP, ventilator-
associated pneumonia; NV ICU-P, non-ventilator ICU pneumo-
nia; AP, aspiration pneumonia; and CS, control subjects.
(TIF)
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found in our study with those found in lung specimens in
three previous studies. Novel phylotypes are not shown.
Actinobacteria are shown in red, Bacteroidetes in yellow, Chlamydiae in
orange, Firmicutes in green, Fusobacteria in purple, Proteobacteria in
blue and Tenericutes in sky blue. The name of the first author of
each study and the name of each bacterium are indicated. The
comparative analysis was conducted using Cytoscape software.
VAP, ventilator-associated pneumonia; CF, Cystic fibrosis.
(TIF)
Figure S4 Molecular methods compared to standard
routine culture for bacteria identification. Bacteria that
were identified by molecular methods (A) and by culture (B)
performed on BAL samples from all patients are presented
according to their classes. Bacterial classes identified by each
method are expressed as a percentage. Bacterial classes and their
corresponding colors are indicated in the bottom.
(TIF)
Figure S5 Molecular methods compared to standard
cultures for fungi identification. Fungi that were identified
by molecular methods (A) or by culture (B) performed on BAL
samples from all patients are presented according to their classes.
Fungal classes identified by each method are expressed as a
percentage. Fungal classes and their corresponding colours are
indicated in the bottom.
(TIF)
Text S1 BAL culture, blood culture and serology
results.
(DOC)
Data S1 Detailed data about the relative abundance and
richness of each species in their corresponding library.
(XLSX)
Data S2 Schematic data about the relative abundance
and richness of each species in the corresponding
library.
(XLSX)
Table S1 Species only detected in BAL from pneumonia
patients by molecular assays.
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Table S2 Species detected in BAL from pneumonia
patients and control subjects by molecular assays.
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subjects by molecular assays.
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Table S4 Molecular repertoire of bacteria identified in
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Table S6 Viruses identified by qPCR and their frequen-
cy in each cohort.
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Table S7 Clinical data in monobacterial, polybacterial,
fungal and/or viral and sterile episodes.
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Table S8 Comparison between culture and molecular
assays performed on BAL specimens.
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Table S9 Clinical and sociodemographic data of pa-
tients and controls.
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